AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7871065 — intervention group
Group type: EXPERIMENTAL
Intervention: Three IM morphine injections (18 mg/70 kg) spaced at 48-h intervals
Number of subjects: 10
Study 7871065 — intervention group
Group type: EXPERIMENTAL
Intervention: Three IM morphine injections (18 mg/70 kg) spaced at 72-h intervals
Number of subjects: 10
Study 7871065 — intervention group
Group type: COMPARATOR
Intervention: Single IM morphine pretreatment (18 mg/70 kg) followed by naloxone challenge (10 mg/70 kg IM)
Number of subjects: 10
Study 2878712 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol chloride (Urecholine) infused intracerebroventricularly with an Infusaid continuous infusion pump
Number of subjects: 0
Study 2878712 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29255066 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 1204
Study 29255066 — intervention group
Group type: EXPERIMENTAL
Intervention: PB-MRD as a primary end point in randomized clinical trials of chemoimmunotherapy in CLL
Number of subjects: 1204
Study 27464461 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried strawberry powder (FDSP) 50 g daily for 1 week
Number of subjects: 25
Study 27464461 — intervention group
Group type: COMPARATOR
Intervention: Control powder
Number of subjects: 25
Study 24981605 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication reconciliation performed at discharge by a hospital pharmacist with communication to the community pharmacist.
Number of subjects: 1176
Study 24981605 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1176
Study 22014959 — intervention group
Group type: EXPERIMENTAL
Intervention: Active swallowing exercises (pharyngocise)
Number of subjects: 58
Study 22014959 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study 22014959 — intervention group
Group type: COMPARATOR
Intervention: Sham swallowing intervention
Number of subjects: 58
Study 20863237 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizer toothpaste and GaAlAs (diode) laser therapy
Number of subjects: 13
Study 20863237 — intervention group
Group type: COMPARATOR
Intervention: Desensitizer toothpaste
Number of subjects: 13
Study 18794896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal fat perfusion (3 g and 9 g safflower oil)
Number of subjects: 16
Study 18794896 — intervention group
Group type: COMPARATOR
Intervention: Ileal placebo infusion after fat-free liquid breakfast (treatment C)
Number of subjects: 16
Study 18794896 — intervention group
Group type: COMPARATOR
Intervention: Fat-free liquid breakfast
Number of subjects: 16
Study 17119044 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based information study arm
Number of subjects: 238
Study 17119044 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-based information study arm
Number of subjects: 238
Study 17119044 — intervention group
Group type: COMPARATOR
Intervention: Wait list control study arm
Number of subjects: 238
Study 17119044 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (video and print)
Number of subjects: 238
Study 17119044 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory analysis
Number of subjects: 238
Study 12139807 — intervention group
Group type: EXPERIMENTAL
Intervention: NPTS with reticulated hyaluronic acid implant
Number of subjects: 168
Study 12139807 — intervention group
Group type: COMPARATOR
Intervention: Traditional trabeculectomy
Number of subjects: 168
Study 11563408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir 2000 mg tid taken within 30 minutes of a meal
Number of subjects: 0
Study 11563408 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir 2000 mg tid taken on an empty stomach
Number of subjects: 0
Study 8541005 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine
Number of subjects: 6
Study 8541005 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg felodipine
Number of subjects: 6
Study 8541005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2031393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 40 mcg prostaglandin E1
Number of subjects: 48
Study 2031393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 7111875 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatic vapors (eucalyptus, menthol, camphor)
Number of subjects: 24
Study 7111875 — intervention group
Group type: COMPARATOR
Intervention: Tap water control
Number of subjects: 24
Study 7111875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal phenylephrine (0.25% solution)
Number of subjects: 24
Study 30689229 — intervention group
Group type: EXPERIMENTAL
Intervention: Real ABM (Approach Bias Modification)
Number of subjects: 56
Study 30689229 — intervention group
Group type: COMPARATOR
Intervention: Sham ABM
Number of subjects: 56
Study 30689229 — intervention group
Group type: EXPERIMENTAL
Intervention: Real ABM
Number of subjects: 56
Study 30689229 — intervention group
Group type: EXPERIMENTAL
Intervention: Real ABM and Sham ABM
Number of subjects: 56
Study 30297499 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen (10 mg/kg every 6 hours until 24 hours after the first convulsion if fever >38.0°C)
Number of subjects: 423
Study 30297499 — intervention group
Group type: COMPARATOR
Intervention: No antipyretics
Number of subjects: 423
Study 30297499 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen
Number of subjects: 423
Study 27092831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV (5 × 10^10 viral particles)
Number of subjects: 87
Study 27092831 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo (1 × 10^8 median tissue culture infective dose)
Number of subjects: 87
Study 27092831 — intervention group
Group type: COMPARATOR
Intervention: Ad26.ZEBOV
Number of subjects: 87
Study 27092831 — intervention group
Group type: COMPARATOR
Intervention: MVA-BN-Filo
Number of subjects: 87
Study 27092831 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 87
Study 24588860 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI group (GP referral to MRI)
Number of subjects: 0
Study 24588860 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (no MRI)
Number of subjects: 0
Study 22336721 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate (0.5 mol/L) injection into the masseter muscle
Number of subjects: 30
Study 22336721 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-injection of ketamine (20 mmol/L) with glutamate
Number of subjects: 30
Study 20200198 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta + inosine
Number of subjects: 0
Study 20200198 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta + placebo
Number of subjects: 0
Study 17872679 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose intrathecal narcotics (ITN) with a combination of 2.5 mg of bupivacaine, 25 microg of fentanyl, and 250 microg of morphine.
Number of subjects: 0
Study 17872679 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia (implied control).
Number of subjects: 0
Study 16078088 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg guanfacine
Number of subjects: 60
Study 16078088 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg guanfacine
Number of subjects: 60
Study 16078088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12384826 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 9
Study 12384826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9766253 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin tolerance test at room temperature (0.1 U per kg of BW, i.v.)
Number of subjects: 0
Study 9766253 — intervention group
Group type: COMPARATOR
Intervention: Insulin tolerance test under increased ambient temperature for 45 min before and after insulin injection
Number of subjects: 0
Study 7802070 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 80
Study 7802070 — intervention group
Group type: COMPARATOR
Intervention: Modified Marshall‐Marchetti‐Krantz urethropexy
Number of subjects: 80
Study 2969535 — intervention group
Group type: EXPERIMENTAL
Intervention: Acylated plasminogen streptokinase activator complex
Number of subjects: 44
Study 2969535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 30355332 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped Classroom (FC) approach
Number of subjects: 282
Study 30355332 — intervention group
Group type: COMPARATOR
Intervention: Traditional classroom approach
Number of subjects: 282
Study 26686957 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg per day
Number of subjects: 3104
Study 26686957 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg per day
Number of subjects: 3104
Study 24452393 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-114 single dose (6, 18, 60, 150, and 300 mg)
Number of subjects: 35
Study 24452393 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-114 multiple doses (14 days consecutively)
Number of subjects: 35
Study 22458335 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-dependent patients
Number of subjects: 31
Study 22458335 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31
Study 20920997 — intervention group
Group type: EXPERIMENTAL
Intervention: XELIRI (capecitabine and irinotecan)
Number of subjects: 450
Study 20920997 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI (infusional 5-fluorouracil and irinotecan)
Number of subjects: 450
Study 18683218 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg monthly for 1 year)
Number of subjects: 163
Study 18683218 — intervention group
Group type: COMPARATOR
Intervention: Observation (no zoledronic acid)
Number of subjects: 163
Study 18683218 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 163
Study 18683218 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 163
Study 15914986 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-containing toothpaste
Number of subjects: 15
Study 15914986 — intervention group
Group type: COMPARATOR
Intervention: Fluoride-free toothpaste
Number of subjects: 15
Study 15086479 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose dialysis
Number of subjects: 1846
Study 15086479 — intervention group
Group type: COMPARATOR
Intervention: Standard dose dialysis
Number of subjects: 1846
Study 10667876 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute session emphasizing the importance of screening for domestic violence
Number of subjects: 0
Study 10667876 — intervention group
Group type: COMPARATOR
Intervention: Unrelated topic session (Control)
Number of subjects: 0
Study 10667876 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in knowledge assessment
Number of subjects: 0
Study 9293855 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (FLU) as salvage chemotherapy, 25 mg/m2 for 5 consecutive days, repeated every 28 days for a maximum of 6 cycles.
Number of subjects: 137
Study 9293855 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-interferon (alpha-IFN) maintenance therapy, 3x10^6 units 3 times per week until disease progression.
Number of subjects: 137
Study 9293855 — intervention group
Group type: COMPARATOR
Intervention: Alpha-interferon (alpha-IFN) maintenance therapy vs no further therapy after FLU response.
Number of subjects: 137
Study 8517952 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0.1 mg/kg per h)
Number of subjects: 91
Study 3771289 — intervention group
Group type: EXPERIMENTAL
Intervention: Training effect observed during the 6-week period
Number of subjects: 5
Study 3771289 — intervention group
Group type: EXPERIMENTAL
Intervention: Coefficient of variation of intra-individual differences
Number of subjects: 5
Study 3771289 — intervention group
Group type: EXPERIMENTAL
Intervention: Coefficient of variation of inter-individual differences
Number of subjects: 5
Study 3771289 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement error
Number of subjects: 5
Study 2783492 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture‐like TENS treatment (10-minute treatment bilaterally to five acupuncture points on the auricle)
Number of subjects: 15
Study 2783492 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo pill)
Number of subjects: 15
Study 31783028 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Vitamin C solution (VCS)
Number of subjects: 240
Study 31783028 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Sodium thiosulfate solution (STS)
Number of subjects: 240
Study 31783028 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (NS)
Number of subjects: 240
Study 30641692 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplements (7 viable strains: Lactobacillus, Bifidobacterium, and Streptococcus) for 6 weeks
Number of subjects: 60
Study 30641692 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 60
Study 28750001 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 42
Study 28750001 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo
Number of subjects: 42
Study 28750001 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 25515658 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) at a dosage of 30 Gy in 10 fractions
Number of subjects: 156
Study 25515658 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 156
Study 25515658 — intervention group
Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 156
Study 23427972 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory teaching approach
Number of subjects: 120
Study 21332742 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% citric acid solution (pH 2.3) for 20 minutes
Number of subjects: 10
Study 21332742 — intervention group
Group type: COMPARATOR
Intervention: Non-acid surface (control)
Number of subjects: 10
Study 19833271 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Group D)
Number of subjects: 40
Study 16789982 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 124655
Study 16789982 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 124655
Study 16789982 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 124655
Study 16789982 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 124655
Study 16789982 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicomorphine
Number of subjects: 124655
Study 16789982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketobemidone
Number of subjects: 124655
Study 16789982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 124655
Study 16789982 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 124655
Study 16789982 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 124655
Study 16789982 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 124655
Study 16789982 — intervention group
Group type: COMPARATOR
Intervention: Dextropropoxiphene
Number of subjects: 124655
Study 16789982 — intervention group
Group type: COMPARATOR
Intervention: ASA and Codeine combination
Number of subjects: 124655
Study 15334532 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 19
Study 15334532 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 19
Study 11314290 — intervention group
Group type: EXPERIMENTAL
Intervention: Hans-Rudolph facemask
Number of subjects: 30
Study 11314290 — intervention group
Group type: COMPARATOR
Intervention: Mouthpiece apparatus
Number of subjects: 30
Study 9143543 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic capillaroscopy
Number of subjects: 35
Study 7954555 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous isosorbide dinitrate
Number of subjects: 30
Study 7954555 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 30
Study 2440203 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunoglobulin against hepatitis A
Number of subjects: 0
Study 2440203 — intervention group
Group type: COMPARATOR
Intervention: Common commercial immunoglobulin
Number of subjects: 0
Study 2440203 — intervention group
Group type: COMPARATOR
Intervention: Nonimmunized subjects
Number of subjects: 0
Study 30019829 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatal approach (study group)
Number of subjects: 16
Study 30019829 — intervention group
Group type: COMPARATOR
Intervention: Buccal approach (control group)
Number of subjects: 16
Study 30019829 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 28844559 — intervention group
Group type: EXPERIMENTAL
Intervention: Active high-frequency rTMS
Number of subjects: 58
Study 28844559 — intervention group
Group type: COMPARATOR
Intervention: Sham high-frequency rTMS
Number of subjects: 58
Study 25500887 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG) 2.5 mg/kg intravenously followed by pegylated G-CSF 6 mg subcutaneously every 2 weeks for 6 doses
Number of subjects: 25
Study 25500887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 25500887 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG) and pegylated G-CSF
Number of subjects: 25
Study 23664121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 30
Study 23664121 — intervention group
Group type: EXPERIMENTAL
Intervention: Social situations
Number of subjects: 30
Study 23664121 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer cannabis use
Number of subjects: 30
Study 23664121 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping strategies
Number of subjects: 30
Study 23664121 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for use
Number of subjects: 30
Study 21395446 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly Fast Facts and Concept (FFAC) e‐mails, 32 e‐mails over 32 weeks
Number of subjects: 82
Study 21395446 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly Fast Facts and Concept (FFAC) e‐mails
Number of subjects: 82
Study 21395446 — intervention group
Group type: COMPARATOR
Intervention: Control group (no e‐mails)
Number of subjects: 82
Study 17935855 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Insertion Technique (MIT)
Number of subjects: 54
Study 17935855 — intervention group
Group type: COMPARATOR
Intervention: Standard Insertion Technique (SIT)
Number of subjects: 54
Study 17190104 — intervention group
Group type: EXPERIMENTAL
Intervention: 4G-beta-D-galactosylsucrose (lactosucrose; LS) 6.0 g twice daily
Number of subjects: 17
Study 17190104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltose; 6.0 g twice daily)
Number of subjects: 17
Study 14707396 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg once daily (o.d.)
Number of subjects: 515
Study 14707396 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 200 microg twice daily (b.i.d.)
Number of subjects: 515
Study 14707396 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg o.d.
Number of subjects: 515
Study 14707396 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 200 microg b.i.d.
Number of subjects: 515
Study 10713292 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 11
Study 10713292 — intervention group
Group type: COMPARATOR
Intervention: Low-energy breakfast
Number of subjects: 11
Study 10713292 — intervention group
Group type: COMPARATOR
Intervention: High-energy breakfast
Number of subjects: 11
Study 10713292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum lunch after exercise and breakfast conditions
Number of subjects: 11
Study 9253878 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg single dose
Number of subjects: 120
Study 9253878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 2053434 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal adjustment (T group)
Number of subjects: 50
Study 2053434 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 50
Study 2053434 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study 6837813 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based practice with enriched dental health education
Number of subjects: 1800
Study 6837813 — intervention group
Group type: COMPARATOR
Intervention: School-based practice without enriched dental health education
Number of subjects: 1800
Study 6837813 — intervention group
Group type: COMPARATOR
Intervention: Private practitioners in the community with enriched dental health education
Number of subjects: 1800
Study 6837813 — intervention group
Group type: COMPARATOR
Intervention: Private practitioners in the community without enriched dental health education
Number of subjects: 1800
Study 30665714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) program with EAP training (N=49)
Number of subjects: 103
Study 30665714 — intervention group
Group type: COMPARATOR
Intervention: Cognitive remediation (CR) program without EAP training (N=54)
Number of subjects: 103
Study 29990524 — intervention group
Group type: EXPERIMENTAL
Intervention: To-Go Group
Number of subjects: 53
Study 29990524 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 53
Study 26661322 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/day)
Number of subjects: 133
Study 26661322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 25458331 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2mg/day for 12 months
Number of subjects: 86
Study 22380537 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 40
Study 22380537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 40
Study 22380537 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 40
Study 22380537 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 40
Study 20429852 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone ER
Number of subjects: 0